ARTS1 Polyclonal Antibody
Applications
Reactivity
Predicted Reactivity
| Overview | |
| Catalog # | bs-7643R |
| Product Name | ARTS1 Polyclonal Antibody |
| Applications |
ELISA
IHC-P
IHC-F
IF(IHC-P)
IF(IHC-F)
IF(ICC)
|
| Reactivity | Human |
| Predicted Reactivity | Mouse, Rat, Dog, Cow, Sheep, Pig, Horse, Rabbit |
| Specifications | |
| Conjugation | Unconjugated |
| Host | Rabbit |
| Source | KLH conjugated synthetic peptide derived from human ARTS1 |
| Immunogen Range | 651-730/941 |
| Clonality | Polyclonal |
| Isotype | IgG |
| Concentration | 1ug/ul |
| Purification | Purified by Protein A. |
| Storage Buffer | 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Storage Condition | Shipped at 4C. Store at -20C for one year. Avoid repeated freeze/thaw cycles. |
| Target | |
| Gene ID | 51752 |
| Subcellular location | Cytoplasm, Cell membrane |
| Synonyms | Endoplasmic reticulum aminopeptidase 1; A LAP; A-LAP; Adipocyte derived leucine aminopeptidase; Adipocyte-derived leucine aminopeptidase; ALAP; Aminopeptidase PILS; APPILS; ARTS 1; ARTS-1; Arts1; Endoplasmic reticulum aminopeptidase 1; ERAAP; ERAP 1; Erap1; ERAP1_HUMAN; PILS AP; PILS-AP; PILSA; PILSAP; Puromycin insensitive leucyl specic aminopeptidase; Puromycin-insensitive leucyl-specic aminopeptidase; Type 1 tumor necrosis factor receptor shedding aminopeptidase regulator; VEGF-induced aminopeptidase. |
| Background | Aminopeptidase that plays a central role in peptide trimming, a step required for the generation of most HLA class I-binding peptides. Peptide trimming is essential to customize longer precursor peptides to fit them to the correct length required for presentation on MHC class I molecules. Strongly prefers substrates 9-16 residues long. Rapidly degrades 13-mer to a 9-mer and then stops. Preferentially hydrolyzes the residue Leu and peptides with a hydrophobic C-terminus, while it has weak activity toward peptides with charged C-terminus. May play a role in the inactivation of peptide hormones. May be involved in the regulation of blood pressure through the inactivation of angiotensin II and/or the generation of bradykinin in the kidney. |
| Application Dilution | |
| ELISA | 1:500-1000 |
| IHC-P | 1:200-400 |
| IHC-F | 1:100-500 |
| IF(IHC-P) | 1:50-200 |
| IF(IHC-F) | 1:50-200 |
| IF(ICC) | 1:50-200 |